The Cyclin Dependent Kinase 2 pipeline drugs market research report outlays comprehensive information on the Cyclin Dependent Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Cyclin Dependent Kinase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Oncology, Infectious Disease, Ear Nose Throat Disorders, and Immunology which include the indications Breast Cancer, Ovarian Cancer, Coronavirus Disease 2019 (COVID-19), Hearing Disorders, Rheumatoid Arthritis, and Inflammation. It also reviews key players involved in Cyclin Dependent Kinase 2 targeted therapeutics development with respective active and dormant or discontinued products.

The Cyclin Dependent Kinase 2 pipeline targets constitutes close to 34 molecules. Out of which, approximately 31 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 11, 3, 2, 12, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 2 molecule.

Cyclin Dependent Kinase 2 overview

Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B).

For a complete picture of Cyclin Dependent Kinase 2’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.